{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:23Z","timestamp":1792804163086,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Locally advanced cervical cancer (LACC) remains a major global health burden, and current imaging-based assessment after standard concurrent chemoradiotherapy (CCRT) is limited by delayed detection of treatment failure and poor sensitivity for microscopic residual disease. Circulating human papillomavirus DNA (HPV ctDNA) represents a tumor-specific biomarker with potential for real-time treatment monitoring. This prospective cohort study aims to evaluate whether dynamic monitoring of plasma HPV ctDNA can predict treatment response and prognosis in patients with LACC receiving CCRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>This single-center, observational cohort study will enroll 57 patients with histologically confirmed LACC (FIGO 2018 stage IB2\u2013IVA) and baseline high-risk HPV infection. All patients will receive standard CCRT including external beam radiotherapy (45\u201350.4 Gy), concurrent weekly cisplatin (40 mg\/m\u00b2), and intracavitary brachytherapy. Peripheral blood samples (10 mL) will be collected at five predefined time points: baseline (T0), mid-treatment (T1), end of CCRT (T2), 3 months post-CCRT (T3), and every 6 months thereafter for 24 months. Plasma HPV ctDNA will be quantified using droplet digital PCR targeting HPV16\/18 E6\/E7 genes. The primary endpoint is progression-free survival (PFS), comparing patients with detectable versus undetectable ctDNA at 3 months post-CCRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study will provide prospective evidence for HPV ctDNA as a minimally invasive biomarker for treatment monitoring and prognostic stratification in LACC, potentially informing future risk-adapted therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1844938","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:40Z","timestamp":1784699560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma HPV ctDNA as a dynamic biomarker for treatment response and prognosis in locally advanced cervical cancer: protocol for a prospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Hailing","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jncc.2024.11.006","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J Natl Cancer Center"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/go.24.00066","article-title":"Toward a framework to assess the financial and economic burden of cervical cancer in low-and middle-income countries: a systematic review","volume":"10","author":"Fuady","year":"2024","journal-title":"JCO Global Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35369","article-title":"Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer","volume":"157","author":"Li","year":"2025","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003001","article-title":"Global challenges of radiotherapy for the treatment of locally advanced cervical cancer","volume":"32","author":"Mayadev","year":"2022","journal-title":"Int J Gynecological Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102959","article-title":"Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis","volume":"138","author":"de Oliveira Andrade","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.997030","article-title":"Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100154","article-title":"HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.","volume":"6","author":"Cabel","year":"2021","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-93152-9","article-title":"Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy","volume":"15","author":"Gupta","year":"2025","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0001050544.16643.94","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000548452","article-title":"HPV ctDNA as a biomarker for monitoring disease progression in HPV16\/18-associated cervical cancer","volume":"93","author":"Kim","year":"2025","journal-title":"Pathobiology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6377","article-title":"Predictive impact of human papillomavirus circulating tumor DNA in treatment response monitoring of HPV\u2010associated cancers; a meta\u2010analysis on recurrent event endpoints","volume":"12","author":"Karimi","year":"2023","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1566750","article-title":"Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis.","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.072176","article-title":"Circulating tumor DNA in cervical cancer: Clinical utility and medico-legal perspectives","volume":"34","author":"Sinno","year":"2025","journal-title":"Oncol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100154","article-title":"HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer","volume":"6","author":"Cabel","year":"2021","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12935-023-03132-0","article-title":"Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker","volume":"23","author":"Li","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int J Gynecology Obstetrics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10147-025-02762-w","article-title":"Utility of circulating human papillomavirus DNA as a biomarker for detection and prognosis of cervical cancer in Japanese patients","author":"Taguchi","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/40.7.1233","article-title":"Limit of blank, limit of detection and limit of quantitation","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa125","article-title":"The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020","volume":"66","author":"Huggett","year":"2020","journal-title":"Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0625","article-title":"Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer","volume":"27","author":"Jeannot","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00954","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer.","volume":"42","author":"Han","year":"2024","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1566750","article-title":"Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Oncol"},{"key":"B23","first-page":"RP101887","article-title":"Monitoring circulating cell-free HPV DNA in metastatic and recurrent cervical cancer: Clinical importance and implications for treatment-a pilot study","volume-title":"Elife","author":"Yin","year":"2025"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cac2.12629","article-title":"Advances in cervical cancer: current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"Cancer Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382008","article-title":"Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer","volume":"14","author":"Beaussire-Trouvay","year":"2024","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01868-6","article-title":"Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions","volume":"127","author":"Herbst","year":"2022","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:41Z","timestamp":1784699561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1844938"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1844938","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1844938"}}